4.6 Article

LRRK2 Levels and Phosphorylation in Parkinson's Disease Brain and Cases With Restricted Lewy Bodies

期刊

MOVEMENT DISORDERS
卷 32, 期 3, 页码 423-432

出版社

WILEY
DOI: 10.1002/mds.26892

关键词

brain; alpha-synuclein; Parkinson's disease; Lewy body; phosphorylation

资金

  1. Michael J. Fox Foundation
  2. Shake It Up Australia Foundation
  3. National Health and Medical Research Council of Australia [1079679]
  4. Reta Lila Weston Trust
  5. Multiple System Atrophy Trust
  6. Alzheimer's Research UK
  7. CBD Solutions
  8. Stichting Parkinson Fonds
  9. Internationale Stichting Alzheimer onderzoek (ISAO)
  10. ZonMW Memorabel Deltaplan Dementia
  11. Reta Lila Weston Institute for Neurological Studies and the Medical Research Council UK
  12. National Institute for Health Research University College London Hospitals Biomedical Research Centre
  13. Grants-in-Aid for Scientific Research [16H06277] Funding Source: KAKEN

向作者/读者索取更多资源

Background: Leucine rich repeat kinase 2 (LRRK2) is a promising target for the treatment of Parkinson's disease; however, little is known about the expression of LRRK2 in human brain and if/how LRRK2 protein levels are altered in Parkinson's disease. Objectives: We measured the protein levels of LRRK2 as well as its phosphorylation on serines 910, 935, and 973 in the postmortem brain tissue of Parkinson's disease patients and aged controls with and without Lewy bodies. Methods: LRRK2 and its phosphorylation were measured by immunoblot in brain regions differentially affected in Parkinson's disease (n = 30) as well as subjects with Lewy bodies restricted to the periphery and lower brain stem (n = 25) and matched controls without pathology (n = 25). Results: LRRK2 levels were increased in cases with restricted Lewy bodies, with a 30% increase measured in the substantia nigra. In clinical Parkinson's disease, levels of LRRK2 negatively correlated to disease duration and were comparable with controls. LRRK2 phosphorylation, however, particularly at serine 935, was reduced with clinical Parkinson's disease with a 36% reduction measured in the substantia nigra. Conclusions: Our data show that LRRK2 phosphorylation is reduced with clinical PD, whereas LRRK2 expression is increased in early potential prodromal stages. These results contribute to a better understanding of the role of LRRK2 in idiopathic Parkinson's disease and may aid efforts aimed at therapeutically targeting the LRRK2 protein. (C) 2016 International Parkinson and Movement Disorder Society

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据